July 29, 2020
First Patient Treated With Hangzhou Valgen Medtech’s DragonFly TMVR Device
July 29, 2020—China-based Hangzhou Valgen Medtech Co., Ltd. announced the completion of the first-in-human use of the company’s DragonFly transcatheter mitral valve repair system.
According to the company, the procedure was performed by Professor Jian’an Wang, MD, and colleagues at the Second Affiliated Hospital of Zhejiang University School of Medicine in Hangzhou, China, along with real-time technical exchange via video link with Professor Scott Lim, MD, from the University of Virginia Medical Center in Charlottesville, Virginia, and Professor Yixian Lin, MD, from Hong Kong Asia Pacific Medical Center in Hong Kong.
The female patient, age 77 years, was diagnosed with severe functional mitral regurgitation and repeated heart failure episodes even after optimal medical treatment. The cardiac team evaluated the patient as unsuitable for surgical thoracotomy.
Prof. Jian'an Wang’s team chose the DragonFly transcatheter mitral valve repair system to perform the edge-to-edge repair operation. The degree of mitral regurgitation decreased to < 2, the patient walked well on the second day after the procedure, and the clinical symptoms were significantly relieved.
In the company’s announcement, Prof. Jian’an Wang commented, “As China’s population is aging, heart valve disease has become a major cardiovascular disease. Transcatheter mitral valve intervention brings hope to these patients who cannot tolerate cardiac surgery due to their advanced age, poor cardiac function, and other organ dysfunctions. In this case, the DragonFly device had achieved excellent operation results. We look forward to further studies to prove the effectiveness and safety of the DragonFly device.”